Treatment | Trial name | Enrollment | Median progression-free survival (months) | Median overall survival (months) | Most frequent grade ≥3 toxicities |
Letrozole plus palbociclib or placebo | PALOMA-2[1,2] | 666 postmenopausal patients, no prior treatment for metastatic disease | 25 versus 15* | 54 versus 51 |
|
Letrozole plus ribociclib or placebo | MONALEESA-2[3,4] | 668 postmenopausal patients, no prior treatment for metastatic disease | 25 versus 16* | 64 versus 51* |
|
Goserelin with either an aromatase inhibitor or tamoxifen plus ribociclib or placebo | MONALEESA-7[5,6] | 672 pre or perimenopausal patients, no prior endocrine treatment for metastatic disease; one line of chemotherapy for advanced disease was permitted | 24 versus 13* | 59 versus 48* |
|
Aromatase inhibitor plus abemaciclib or placebo | MONARCH3[7] | 493 postmenopausal patients, no prior treatment for metastatic disease | 28 versus 15* | 67 versus 55 |
|
HER2: human epidermal growth factor 2.
* Statistically significant.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟